TY - JOUR
T1 - Adult height is associated with increased risk of ovarian cancer
T2 - a Mendelian randomisation study
AU - Dixon-Suen, Suzanne C
AU - Nagle, Christina M
AU - Thrift, Aaron P
AU - Pharoah, Paul D P
AU - Ewing, Ailith
AU - Pearce, Celeste Leigh
AU - Zheng, Wei
AU - Chenevix-Trench, Georgia
AU - Fasching, Peter A
AU - Beckmann, Matthias W
AU - Lambrechts, Diether
AU - Vergote, Ignace
AU - Lambrechts, Sandrina
AU - Van Nieuwenhuysen, Els
AU - Rossing, Mary Anne
AU - Doherty, Jennifer A
AU - Wicklund, Kristine G
AU - Chang-Claude, Jenny
AU - Jung, Audrey Y
AU - Moysich, Kirsten B
AU - Odunsi, Kunle
AU - Goodman, Marc T
AU - Wilkens, Lynne R
AU - Thompson, Pamela J
AU - Shvetsov, Yurii B
AU - Dörk, Thilo
AU - Park-Simon, Tjoung-Won
AU - Hillemanns, Peter
AU - Bogdanova, Natalia
AU - Butzow, Ralf
AU - Nevanlinna, Heli
AU - Pelttari, Liisa M
AU - Leminen, Arto
AU - Modugno, Francesmary
AU - Ness, Roberta B
AU - Edwards, Robert P
AU - Kelley, Joseph L
AU - Heitz, Florian
AU - du Bois, Andreas
AU - Harter, Philipp
AU - Schwaab, Ira
AU - Karlan, Beth Y
AU - Lester, Jenny
AU - Orsulic, Sandra
AU - Rimel, Bobbie J
AU - Kjær, Susanne K
AU - Høgdall, Estrid
AU - Jensen, Allan
AU - Høgdall, Claus K
AU - Lundvall, Lene
AU - Australian Ovarian Cancer Study Group
PY - 2018/4
Y1 - 2018/4
N2 - BACKGROUND: Observational studies suggest greater height is associated with increased ovarian cancer risk, but cannot exclude bias and/or confounding as explanations for this. Mendelian randomisation (MR) can provide evidence which may be less prone to bias.METHODS: We pooled data from 39 Ovarian Cancer Association Consortium studies (16,395 cases; 23,003 controls). We applied two-stage predictor-substitution MR, using a weighted genetic risk score combining 609 single-nucleotide polymorphisms. Study-specific odds ratios (OR) and 95% confidence intervals (CI) for the association between genetically predicted height and risk were pooled using random-effects meta-analysis.RESULTS: Greater genetically predicted height was associated with increased ovarian cancer risk overall (pooled-OR (pOR) = 1.06; 95% CI: 1.01-1.11 per 5 cm increase in height), and separately for invasive (pOR = 1.06; 95% CI: 1.01-1.11) and borderline (pOR = 1.15; 95% CI: 1.02-1.29) tumours.CONCLUSIONS: Women with a genetic propensity to being taller have increased risk of ovarian cancer. This suggests genes influencing height are involved in pathways promoting ovarian carcinogenesis.
AB - BACKGROUND: Observational studies suggest greater height is associated with increased ovarian cancer risk, but cannot exclude bias and/or confounding as explanations for this. Mendelian randomisation (MR) can provide evidence which may be less prone to bias.METHODS: We pooled data from 39 Ovarian Cancer Association Consortium studies (16,395 cases; 23,003 controls). We applied two-stage predictor-substitution MR, using a weighted genetic risk score combining 609 single-nucleotide polymorphisms. Study-specific odds ratios (OR) and 95% confidence intervals (CI) for the association between genetically predicted height and risk were pooled using random-effects meta-analysis.RESULTS: Greater genetically predicted height was associated with increased ovarian cancer risk overall (pooled-OR (pOR) = 1.06; 95% CI: 1.01-1.11 per 5 cm increase in height), and separately for invasive (pOR = 1.06; 95% CI: 1.01-1.11) and borderline (pOR = 1.15; 95% CI: 1.02-1.29) tumours.CONCLUSIONS: Women with a genetic propensity to being taller have increased risk of ovarian cancer. This suggests genes influencing height are involved in pathways promoting ovarian carcinogenesis.
U2 - 10.1038/s41416-018-0011-3
DO - 10.1038/s41416-018-0011-3
M3 - Journal article
C2 - 29555990
VL - 118
SP - 1123
EP - 1129
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 8
ER -